Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar “Oral Delivery of Therapeutic Proteins – Oramed Story” on November 18, 2020

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific Officer Dr. Miriam  Kidron will join Premas Biotech’s Co-Founder and Managing Director Dr. Prabuddha Kundu and Co-Founder and Chief Operating Officer Dr. Nupur Mehrotra in Part 2 of a webinar titled “Oral Delivery of Therapeutic Proteins – Oramed Story” on Wednesday, November 18, 2020 at 10:00 a.m. ET.  Prof. Hershko is a member of the Oramed Scientific Advisory Board.

Investors are invited to register for the webinar at:

Throughout history, oral administration has been regarded as the most convenient mode of drug delivery, as it requires minimal expertise and invasiveness. Although oral delivery works well for small-molecule drugs, oral delivery of proteins and peptides has been limited by acidic conditions in the stomach and low permeability across the intestinal epithelium.

Oramed has made tremendous strides in the oral delivery of proteins and peptides, beginning with its oral insulin ORMD-0801 which is entering Phase 3 trials in the U.S.

On Wednesday at 10:00 a.m. ET, in the conclusion of a two-part webinar series, the session will focus on the “Oral Delivery of Therapeutic Proteins – Oramed Story”.

About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

For more information, please visit

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes or revolutionizing the treatment of diabetes with our products. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact

Estee Yaari

[email protected]

Logo –

Cision View original content:—oramed-story-on-november-18-2020-301171749.html

SOURCE Oramed Pharmaceuticals Inc.